ライフサイエンスコーパス: procalcitonin

1 -62%) and a specificity of 91% (76%-98%) for procalcitonin.

2 unts, C-reactive protein, interleukin-6, and procalcitonin.

3 aminoterminal portion of porcine prohormone procalcitonin.

4 biomarkers including C-reactive protein and procalcitonin.

5 ry rate corrected associations with elevated procalcitonin.

6 aled functional modules specific to elevated procalcitonin.

7 sitivity and specificity compared with serum procalcitonin.

8 tudy heterogeneity higher for serum than CSF procalcitonin.

9 atios to identify sepsis, in comparison with procalcitonin.

10 ive protein and 0.78 (95% CI, 0.68-0.87) for procalcitonin.

11 adrenomedullin (0.70; 95% CI, 0.59-0.82) and procalcitonin (0.71; 95% CI, 0.60-0.83) compared with C-

12 adrenomedullin (0.81; 95% CI, 0.71-0.92) and procalcitonin (0.73; 95% CI, 0.60-0.85) each had a great

13 erial infection at ICU admission, similar to procalcitonin (0.85 [95% CI, 0.79-0.90]; P = .79) and si

14 (0.85-0.96), MMP8/HLA-DRA: 0.89 (0.84-0.95), procalcitonin: 0.80 (0.73-0.88) (AUROC, confidence inter

15 Procalcitonin (-1.23 [-1.61 to -0.85]; p < 0.001), but n

16 ritin, 417 ng/mL; 95% CI, 228-607 ng/mL; and procalcitonin, 1.45 ng/mL; 95% CI, 0.13-2.77 ng/mL).

17 rategies to minimize antibiotic use included procalcitonin (14 randomized clinical trials), clinical

18 positive procalcitonin (39.7%) and negative procalcitonin (38.4%) at admission.

19 ood culture sampled patients with a positive procalcitonin (39.7%) and negative procalcitonin (38.4%)

20 0.7-15.3] vs. 3.7 [0.6-9.8], p=.68) and peak procalcitonin (4.5 [1.0-22.9] vs. 5.0 [0.9-16.0], p=.91)

21 .25-32.62); MMP8/HLA-DRA: 8.03 (2.10-30.76), procalcitonin: 4.20 (1.15-15.43) [odds ratio (confidence

22 Inhibition of procalcitonin activation by dipeptidyl-peptidase 4 (DPP4

23 was associated with higher concentrations of procalcitonin, activation of the innate immune system (%

24 mission plasma levels of C-reactive protein, procalcitonin, adrenomedullin (either bioavailable adren

25 lator-associated pneumonia) and ineffective (procalcitonin algorithm for antibiotic deescalation) app

26 e assigned to receive antibiotics based on a procalcitonin algorithm or usual care by searching the C

27 Procalcitonin algorithms may reduce antibiotic use for a

28 Procalcitonin alone reliably discriminated between those

29 High serum procalcitonin and bacterial adjudication were more often

30 sor to detect multiple biomarkers (troponin, procalcitonin and C-Reactive Protein) in parallel in und

31 4.4% of the intensive care unit stays in the procalcitonin and control groups, respectively (p=.11).

32 such as C-reactive proteins, interleukin-6, procalcitonin and ferritin.

33 The FAIM3:PLAC8 ratio outperformed plasma procalcitonin and IL-8 and IL-6 in discriminating betwee

34 Procalcitonin and interleukin-6 (IL-6) levels were used

35 Area under the curve for procalcitonin and interleukin-6, 24 hours after out-of-h

36 lmonary bypass increase in concentrations of procalcitonin and interleukin-8, but not of interleukin-

37 Both procalcitonin and lactate reliably discriminated between

38 , and C-reactive protein peaked earlier than procalcitonin and leukopenia.

39 Embedding procalcitonin and other biomarkers into multifaceted ste

40 al record best practice alert (BPA) based on procalcitonin and respiratory polymerase chain reaction

41 The 116 amino acid prohormone procalcitonin and some of its component peptides (collec

42 -terminal pro-B-type natriuretic peptide and procalcitonin and the changes in hemodynamic variables a

43 lated with concentrations of interleukin 27, procalcitonin and the kynurenine-tryptophan ratio.

44 to antimicrobial therapy, proadrenomedullin, procalcitonin, and C-reactive protein levels all signifi

45 thereafter, and the serum proadrenomedullin, procalcitonin, and C-reactive protein levels were measur

46 ompared the diagnostic accuracies of MDW and procalcitonin, and five studies compared the diagnostic

47 and had higher serum lactate dehydrogenase, procalcitonin, and interleukin-6 levels.

48 st common clinically used sepsis biomarkers, procalcitonin, and its roles in sepsis management in the

49 od inflammation markers (C-reactive protein, procalcitonin, and leukocyte count) were not significant

50 vels of high-sensitivity C-reactive protein, procalcitonin, and lipopolysaccharide at admission.

51 Adjudicators, blinded to C-reactive protein, procalcitonin, and MeMed BV (MMBV), labeled each case (b

52 High expressions of the CALCA gene, procalcitonin, and NPCT were detected in the lung tissue

53 of NPCT decreased pulmonary levels of CALCA, procalcitonin, and NPCT; reduced lung inflammation and i

54 roadrenomedullin, cystatin-C, interleukin-6, procalcitonin, and others.

55 scular endothelial growth factor, protein C, procalcitonin, and proadrenomedullin were measured in ar

56 IL-1Ra), IL-8, IL-10, IL-18 binding protein, procalcitonin, and protein C in plasma did not differ be

57 macroglobulin, haptoglobin, serum amyloid P, procalcitonin, and tissue plasminogen activator) were si

58 N-terminal pro-B-type natriuretic peptide, procalcitonin, and waveform analysis of changes in strok

59 0.89 (P < 0.001), therefore, competing with procalcitonin (area under the curve = 0.86, P < 0.001).

60 I, 0.85-0.99) and significantly outperformed Procalcitonin (area under the receiver operating charact

61 stigate the utility of proadrenomedullin and procalcitonin as diagnostic and prognostic biomarkers in

62 red to elucidate the source and action(s) of procalcitonin as well as its relationship to cytokine ac

63 Plasma procalcitonin at admission was significantly higher in c

64 les were able to detect the sepsis biomarker procalcitonin at clinically relevant concentrations with

65 Determine if procalcitonin at the time of initial rapid response team

66 Recent trials suggest procalcitonin-based guidelines can reduce antibiotic use

67 rences in the median serum concentrations of procalcitonin between patients with positive bronchoalve

68 patients with cancer, proadrenomedullin and procalcitonin both have a promising role in predicting b

69 Procalcitonin, but not high-sensitivity C-reactive prote

70 S. study indicate that inability to decrease procalcitonin by more than 80% is a significant independ

71 Plasma levels of heparin-binding protein, procalcitonin, C-reactive protein, lactate, and leukocyt

72 lications were obtained using the MeSH terms procalcitonin, C-reactive protein, sepsis, and biologica

73 We evaluated the association between serum procalcitonin concentration at hospital admission with p

74 han those patients who died of heatstroke; a procalcitonin concentration of >0.5 ng/mL (>0.15 nmol/L)

75 The procalcitonin concentration subsequently increased to a

76 ents who survived had a significantly higher procalcitonin concentration than those patients who died

77 Median procalcitonin concentration was lower with viral pathoge

78 mly assigned to receive antibiotics based on procalcitonin concentrations (procalcitonin-guided group

79 s of interest was the relationship between a procalcitonin decrease of more than 80% from baseline to

80 2 hrs) was retrieved, frozen, and stored for procalcitonin determination.

81 Procalcitonin did not assist in the early diagnosis of s

82 The accuracy of C-reactive protein and procalcitonin did not differ at any postoperative day.

83 Procalcitonin did not differ between sepsis and "no seps

84 Finally, procalcitonin did not help improve concordance between t

85 all-cause mortality was two-fold higher when procalcitonin did not show a decrease of more than 80% f

86 Procalcitonin discriminated bacterial pathogens, includi

87 Procalcitonin discriminated between typical bacteria and

88 Procalcitonin dynamics were similar between surgical and

89 s were measured on day 1 and day 3 using the procalcitonin enzyme-linked fluorescent assay.

90 ompared the LFA to standard EIA and included procalcitonin evaluation.

91 mental to interleukin-6, C-reactive protein, procalcitonin, ferritin, D-dimer, cardiac troponin T, an

92 stration approved the blood infection marker procalcitonin for guiding antibiotic therapy in patients

93 C-reactive protein is more accurate than procalcitonin for the detection of infectious complicati

94 eactive protein was more discriminating than procalcitonin for the detection of intra-abdominal infec

95 The utility of procalcitonin for the diagnosis of infection in the crit

96 nd critical post-neurosurgical patients, CSF procalcitonin gains superior sensitivity and specificity

97 and includes topics such as the serum marker procalcitonin, gene expression profiling, matrix-assiste

98 r transfection of a chimeric cDNA encoding a procalcitonin-GIF fusion protein into the helper cell-de

99 selected subgroups only (C-reactive protein, procalcitonin, glucometer).

100 There were 258 patients in the procalcitonin group and 251 patients in the control grou

101 patients were randomized: 49 patients to the procalcitonin group and 45 patients to the C-reactive pr

102 fection was 7.0 (Q1-Q3, 6.0-8.5) days in the procalcitonin group and 6.0 (Q1-Q3, 5.0-7.0) days in the

103 Patients were randomized in two groups: the procalcitonin group and the C-reactive protein group.

104 nt of withheld treatment was observed in the procalcitonin group of patients classified by the intens

105 Treatment failure occurred in 398 procalcitonin group patients (19.1%) and in 466 control

106 The procalcitonin group was considered superior if the durat

107 groups: one using the procalcitonin results (procalcitonin group) and one being blinded to the procal

108 8 deaths in 2085 patients (5.7%) assigned to procalcitonin groups compared with 134 deaths in 2126 co

109 Procalcitonin guidance was also associated with a 2.4-da

110 Procalcitonin guidance was not associated with increased

111 Neither procalcitonin-guided antibiotic treatment (0.91 [0.82-1.

112 ose per 100 intensive care unit days using a procalcitonin-guided approach.

113 n-admission and risk assessment of admission procalcitonin-guided clinical decisions is warranted.

114 otics based on procalcitonin concentrations (procalcitonin-guided group) or control.

115 tality at 30 days was significantly lower in procalcitonin-guided patients than in control patients (

116 in control patients (286 [9%] deaths in 3336 procalcitonin-guided patients vs 336 [10%] in 3372 contr

117 Despite shorter antibiotic duration, neither procalcitonin-guided therapy (0.93 [0.84-1.03]; p = 0.15

118 ential analyses of mortality associated with procalcitonin-guided therapy did not reach the trial seq

119 ration of antibiotic therapy is reduced with procalcitonin-guided therapy or prespecified limited dur

120 Outcome data from procalcitonin-guided therapy trials have shown similar m

121 lled trials was designed to assess safety of procalcitonin-guided treatment in patients with acute re

122 Procalcitonin has been evaluated as a biochemical tool t

123 Procalcitonin has been evaluated in several studies with

124 Procalcitonin has emerged as the inflammatory marker mos

125 rker POCTs, including C-reactive protein and procalcitonin, has the potential to improve the clinical

126 halved the diagnostic error rate compared to procalcitonin in all tested cohorts and cohort combinati

127 significantly associated with elevations in procalcitonin in cohorts who were and were not infected

128 MMP8/HLA-DRA, LCN2/HLA-DRA outperformed procalcitonin in differentiating between patients with s

129 However, proadrenomedullin was superior to procalcitonin in predicting response in all febrile pati

130 ew guidelines, further delineate the role of procalcitonin in predicting UTI, and explore the role of

131 C-reactive protein was as useful as procalcitonin in reducing antibiotic use in a predominan

132 uracy of the infectious diagnosis when using procalcitonin in the intensive care unit and of the diag

133 edictive abilities of C-reactive protein and procalcitonin in the occurrence of IAIs after elective c

134 Objectives: We determined how procalcitonin induces endothelial hyperpermeability and

135 Procalcitonin is a biomarker used to monitor bacterial i

136 Procalcitonin is a reliable prognostic marker of septic

137 ative urinalysis/dipstick test result, serum procalcitonin less than or equal to 0.5 ng/mL, and blood

138 sinophil count <50/uL (2.53 [1.61-3.98], and procalcitonin level >0.25ng/mL (2.8 [1.65-4.73]).

139 included patients 18 years and older with a procalcitonin level <0.25 ng/mL and a virus identified o

140 The change in procalcitonin level in patients with intensive care unit

141 Thus, a procalcitonin level is unlikely to provide reliable evid

142 .37-0.77]; P = .006), marginally better than procalcitonin levels (0.65 [95% CI, 0.50-0.79]; P = .06)

143 probably viral etiology had the lowest peak procalcitonin levels (1.7 [25th-75th percentiles, 1.6-1.

144 interval, 1.01-1.31; p = .04) and increasing procalcitonin levels (adjusted odds ratio, 5.63; 95% con

145 (hazard ratio=1.23 [1.01-1.49]; p=0.04) and procalcitonin levels (hazard ratio=1.20 [1.03-1.39]; p=0

146 e care unit transfer had significantly lower procalcitonin levels (median 0.28 ng/mL [interquartile r

147 changes in metabolites over time relative to procalcitonin levels adjusted for age, Simplified Acute

148 studies analyzing C-reactive protein and/or procalcitonin levels at postoperative days 2, 3, 4, and/

149 vely validate that the inability to decrease procalcitonin levels by more than 80% between baseline a

150 In addition, after treatment, procalcitonin levels decreased significantly from 44 ng/

151 s whether the sensitivity and specificity of procalcitonin levels enable the practitioner to distingu

152 Procalcitonin levels for intensive care unit transfers f

153 Serum procalcitonin levels had poor diagnostic value in separa

154 ions of current diagnostic modalities, serum procalcitonin levels have been proposed as a novel tool

155 nts and Main Results: Elevated postoperative procalcitonin levels identified patients with 2-fold inc

156 Preliminary results suggest procalcitonin levels in patients at the time of initial

157 The procalcitonin levels of patients with noninfectious inte

158 shorter in those who had a decrease in their procalcitonin levels on day 3 from baseline compared wit

159 ardiac arrest (all p values<0.001), but only procalcitonin levels showed overall differences between

160 Procalcitonin levels showed wide dispersion.

161 a prospective observational clinical study, procalcitonin levels were assessed in 50 patients who un

162 Procalcitonin levels were measured daily for 10 days and

163 Serial serum procalcitonin levels were measured on day 1 and day 3 us

164 9% of the cases with confirmed infection had procalcitonin levels<0.25 microg/L.

165 n in addition to high C-reactive protein and procalcitonin levels.

166 included patients 18 years and older with a procalcitonin < 0.25 ng/ml and a virus identified on res

167 Systematic reviews of procalcitonin, mannose-binding lectin and molecular ampl

168 However, serial measurements of serum procalcitonin may be helpful in predicting survival from

169 The challenges and limitations of procalcitonin measurement in sepsis are also discussed.

170 In comparison, the sensitivity of procalcitonin measurement was 28.6% (95% CI, 16.2%-40.9%

171 atients with febrile ARI and was superior to procalcitonin measurement.

172 Procalcitonin measuring for the initiation of antimicrob

173 We investigated whether a set of biomarkers (procalcitonin, MR-pro-adrenomedullin, CT-pro-endothelin-

174 , serum lactate, platelet count, fibrinogen, procalcitonin, multi-organ dysfunction syndrome, Pediatr

175 elevated C-reactive protein, serum ferritin, procalcitonin, N-terminal pro B-type natriuretic peptide

176 0.96-0.99) in predicting sepsis but not for procalcitonin (not significant; 95% CI, 0.29-0.46).

177 edicting death with an odds ratio of 4.0 vs. procalcitonin (odds ratio 3.2), interleukin-6 (odds rati

178 eukin-17A inhibits the deleterious effect of procalcitonin on disease outcome.

179 in was also significantly more accurate than procalcitonin on the fourth postoperative day (areas und

180 Diagnostic stewardship of procalcitonin-on-admission and risk assessment of admiss

181 At 65 study hospitals, procalcitonin-on-admission demonstrated poor sensitivity

182 ) was calculated to assess discrimination by procalcitonin-on-admission for BSI in patients with and

183 Combining IMX-BVN-3 and IMX-SEV-3 with procalcitonin or IL-6 levels or SOFA scores did not sign

184 ted levels of venous lactate, creatinine, or procalcitonin; or low platelet or lymphocyte counts.

185 hydrogenase (LDH) (P < .0001); and increased procalcitonin (P < .0001).

186 curve for predicting favorable response than procalcitonin (p < 0.0001).

187 howed that proadrenomedullin (p = 0.005) and procalcitonin (p = 0.009) each had a better performance

188 lprotectin levels positively correlated with procalcitonin (P = 0.014), thrombocyte counts (P = 0.001

189 roup and levels of interleukin-6 (p=0.25) or procalcitonin (p=0.85).

190 iated with increased concentrations of serum procalcitonin, particularly among survivors.

191 of C-reactive protein (CRP) (2-200 mug/mL), procalcitonin (PCT) (0.2-50 ng/mL), and interleukin 6 (I

192 However, conventional biomarkers such as procalcitonin (PCT) and C-reactive protein (CRP) have li

193 critically ill adults with suspected sepsis, procalcitonin (PCT) and C-reactive protein (CRP) monitor

194 Amyloid A (SAA), C - reactive protein (CRP), Procalcitonin (PCT) and Lipopolysaccharide-binding prote

195 infections with recent growing attention to procalcitonin (PCT) and pro-adrenomedullin (proADM).

196 as augmented by measuring the serum level of procalcitonin (PCT) as a marker of bacterial infection.

197 The procalcitonin (PCT) assay is an accurate screening test

198 Procalcitonin (PCT) has been shown to be a useful surrog

199 Accurate determination of procalcitonin (PCT) is highly crucial in bacterial infec

200 Procalcitonin (PCT) is increasingly utilized to determin

201 Procalcitonin (PCT) is synthesized by a large number of

202 European studies suggest that the serum procalcitonin (PCT) level may be used to guide antibioti

203 The interpretation of serum procalcitonin (PCT) levels in septic patients is facilit

204 tivity of blood C-reactive protein (CRP) and procalcitonin (PCT) measured by Point-of-Care tests (PoC

205 multicentric, observational study to test if Procalcitonin (PCT) might be an early and reliable marke

206 he present study is to assess the ability of procalcitonin (PCT) to differentiate between periodontal

207 Studies have shown that the use of procalcitonin (PCT) to guide the decision to initiate an

208 Procalcitonin (PCT) was &0.25 ng/ml in 52 (83%) EIA+ pat

209 r expressed on myeloid cells-1 (sTREM-1) and procalcitonin (PCT) were assayed, and the expression of

210 n reaction, urinary antigen tests, and serum procalcitonin (PCT) were done in nearly all cases.

211 Procalcitonin (PCT), a marker of bacterial sepsis, may a

212 (EGOFET) was developed for the detection of procalcitonin (PCT), a sepsis marker.

213 T) device was developed for the detection of procalcitonin (PCT), a specific and early marker for sep

214 The role of procalcitonin (PCT), a widely used sepsis biomarker, in

215 uated by its application to the detection of procalcitonin (PCT), an important biomarker for sepsis.

216 actate, respiratory rate, oxygen saturation, procalcitonin (PCT), and C-reactive protein (CRP) with a

217 cell count (WBC), C-reactive protein (CRP), procalcitonin (PCT), and interleukin-6 (IL-6).

218 shed markers IL-6, C-reactive protein (CRP), procalcitonin (PCT), and soluble urokinase plasminogen a

219 IA, high-sensitive C-reactive protein (CRP), procalcitonin (PCT), neutrophil percentage (N%), and lac

220 d cell count, absolute neutrophil count, and procalcitonin (PCT), specifically PCT <0.25 mug/L, were

221 d cell count, absolute neutrophil count, and procalcitonin (PCT), specifically PCT <0.25 ug/L, were s

222 es, the liver seems to be the main source of procalcitonin (PCT), which has been shown to increase in

223 Randomized trials support use of procalcitonin (PCT)-based algorithms to decrease duratio

224 Whether procalcitonin (PCT)-guided antibiotic management in pati

225 ctors [i.e., interleukin-3 (IL-3), IL-6, and procalcitonin (PCT)].

226 1, soluble tumor necrosis factor receptor-1, procalcitonin [PCT], C-reactive protein [CRP]) activatio

227 dogenous peptide derived from the prohormone procalcitonin, plays a critical role in the development

228 In patients with post-traumatic sepsis, procalcitonin positively correlates with systemic interl

229 Mechanistically, procalcitonin potentiates proinflammatory cytokine expre

230 The use of procalcitonin (ProCT) as a marker of several clinical co

231 y aims to investigate the levels of salivary procalcitonin (ProCT) in patients with different periodo

232 We investigated procalcitonin (ProCT) levels in the serum and saliva of

233 strates, for the first time, the presence of procalcitonin (ProCT), an established serum marker of in

234 Procalcitonin (ProCT), the precursor to the calcitonin h

235 othelial hyperpermeability and how targeting procalcitonin protects vascular barrier integrity.

236 Widespread implementation of procalcitonin protocols in patients with acute respirato

237 Procalcitonin reacted to LPS insult late.

238 Amino-prohormone procalcitonin-reactive antiserum administration resulted

239 At 65 procalcitonin-reporting hospitals, 74,958 of 739,130 pat

240 Clinically, procalcitonin represents the most widely used biomarker

241 lcitonin group) and one being blinded to the procalcitonin results (control group).

242 re randomized into two groups: one using the procalcitonin results (procalcitonin group) and one bein

243 Conclusions: Targeting procalcitonin's action on the endothelium is a feasible

244 ardship practices have limited confidence in procalcitonin's benefit.

245 ter fixed-duration therapy becomes standard, procalcitonin's utility in the ICU may decline.

246 Procalcitonin seems not to have added value as compared

247 Procalcitonin serum level was obtained for all consecuti

248 development of SIRS should be investigated; procalcitonin serum levels can help to identify patients

249 ntly introduced antimigraine drugs, inhibits procalcitonin signaling and increases survival time in s

250 ene-related peptide receptor as relevant for procalcitonin signaling and suggests a potential therape

251 Effects of the procalcitonin signaling pathway on endothelial barrier a

252 en viral and bacterial pathogens, but higher procalcitonin strongly correlated with increased probabi

253 nfection and organ dysfunction, most notably procalcitonin, substantially improve early prediction of

254 ion layer) served to selectively capture the procalcitonin target analyte.

255 procalcitonin testing did not have a repeat procalcitonin test.

256 Most patients (83%) who had admission day procalcitonin testing did not have a repeat procalcitoni

257 admission blood cultures also had admission procalcitonin testing.

258 For MDW versus procalcitonin, the area under the SROC was similar (0.88

259 Procalcitonin, the precursor peptide of calcitonin, has

260 A procalcitonin threshold of 0.1 ng/mL resulted in 80.9% (

261 No procalcitonin threshold perfectly discriminated between

262 The ability of procalcitonin to differentiate between certain or probab

263 However, the accuracy of procalcitonin to discriminate between viral and bacteria

264 Accuracy of procalcitonin to discriminate between viral and bacteria

265 spiratory tract infection, is measurement of procalcitonin to guide antibiotic prescriptions associat

266 INTERPRETATION: Use of procalcitonin to guide antibiotic treatment in patients

267 The measurement of procalcitonin to guide initiation and duration of antibi

268 Use of procalcitonin to guide initiation and duration of antibi

269 ed to survived had significantly higher CRP, procalcitonin, Troponin-T, ferritin, and total-lung-scor

270 C-reactive protein (CRP), procalcitonin, tumor necrosis factor alpha, interleukin

271 s in which no infection was confirmed, had a procalcitonin value>1microg/L and 14.9% of the cases wit

272 rgical infected cohorts had similar baseline procalcitonin values (3.0 [0.7-15.3] vs. 3.7 [0.6-9.8],

273 Shock had an association with higher procalcitonin values independent of the presence of infe

274 Herein, we report procalcitonin values relative to baseline patient charac

275 at admission had a trend toward higher peak procalcitonin values than did those whose infection deve

276 Trends in differences in procalcitonin values were seen in patients who had incid

277 Median procalcitonin varied considerably by pathogen, BSI sourc

278 CI, 0.63-0.91); pooled sensitivity of serum procalcitonin was 0.65 (95% CI, 0.33-0.88), specificity

279 surgical patients, pooled sensitivity of CSF procalcitonin was 0.82 (95% CI, 0.53-0.95), specificity

280 CI, 0.66-0.91); pooled sensitivity of serum procalcitonin was 0.82 (95% CI, 0.58-0.94), specificity

281 In adults, pooled sensitivity of CSF procalcitonin was 0.89 (95% CI, 0.71-0.96), specificity

282 CI, 0.72-0.97); pooled sensitivity of serum procalcitonin was 0.90 (95% CI, 0.75-0.97), specificity

283 In children, pooled sensitivity of CSF procalcitonin was 0.96 (95% CI, 0.88-0.99), specificity

284 The mean serum procalcitonin was elevated 20-fold on admission in patie

285 A delta in performance between MMBV and procalcitonin was maintained across the different cohort

286 Procalcitonin was measured daily over the first 5 days.

287 solute reduction in antibiotic duration with procalcitonin was only one day.

288 Interestingly, procalcitonin was only significantly increased in patien

289 We sought to evaluate whether procalcitonin was superior to C-reactive protein in guid

290 A rapid immunochemical assay for serum procalcitonin was utilized.

291 inflammation, assessed by interleukin-6 and procalcitonin, was independently associated with increas

292 is, the sensitivity and specificity of serum procalcitonin were 0.55 (95% confidence interval [CI], .

293 Elevated d-dimer, C-reactive protein, and procalcitonin were associated with renal replacement the

294 tor, vascular endothelial growth factor, and procalcitonin were elevated but not differentially affec

295 ESR, CRP, fibrinogen, ferritin, and procalcitonin were higher in patients with thrombotic co

296 C-reactive protein and procalcitonin were measured daily until the fourth posto

297 a, interferon-gamma, C-reactive protein, and procalcitonin were measured.

298 ukin-8, transforming growth factor-beta, and procalcitonin were subsequently analyzed using enzyme-li

299 Addition of procalcitonin with a cutoff level of 0.25 ng/mL improved

300 his study addressed the correlation of serum procalcitonin with the course of classic (nonexertional)